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Background
Patients with asthma may accelerate the average decline in
lung function that is related to ageing (±30ml/year) [1].
The aim of this study was to identify risk factors for
decline in lung function in patients with severe asthma.
Methods
Prospective cohort with 9 years of follow up. Inclusion cri-
teria: diagnosis of asthma and at least one year of use of
inhaled corticosteroids before enrollment. Every three
months patients had a multidisciplinary evaluation and
they received free medication (inhaled corticosteroids,
long-acting and short-acting b-agonists) monthly. Spirome-
try was performed anually in a Koko® spirometer accord-
ing to the ATS protocol. Brazilian standards reported by
Pereira [2] were used as normal reference values.
Results
Interim analysis of 94 patients is present herein. Eighty
(85.1%) patients were female. Their mean age(+SD) was
53.37(+14.19)years. 49(52.1%) of them were overweighted
or obese according to bioimpedance measurements. Eigth
patients(8.51%) had no immediate reversibility after
bronchodilator use, measured by FEV1. Median (interquar-
tile range)values of lung function at baseline were: FEV1pre-
BD1.76L(1.38-2.2) - 67%(55.25-81.5) of predicted, FEV1post-
BD1,86L(1.55-2.41)- 75%(63-88). After 9 years of follow up,
lung function values were: FEV1pre-BD1.54L(1.21-1.97)-
64.3%(50.6-76.3), FEV1post-BD1.77L(1.38-2.23)-71.04%
(57.64-83.43).Reversibility to bronchodilator was stable
throughout the study. During the follow up,there was a
decline of 10mL/year in FEV1(post-BD). Thirty patients had
uncontrolled asthma by ACQ score in their last evaluation.
Among these patients, we found lower lung function and
more reversibility to bronchodilator in the end of the study
with FEV1pre-BD1,35L(1,15-1,81), indicating a reduction
of 45mL/year in basal function, but they have better
reversibility with median(IR) 275mL(153-388) and 17.3%
(11.16-29.6). 56.4% patients had positive skin prick test to
aeroallergens. Lung function in patients with a negative
test, was lower [median (IR) FEV1pre-BD1.42L(1.14-1.81)] in
comparison to FEV1pre-BD1.67L(1.26-2.23)among atopics,
the non atopics presenting a decline of 38mL/year in their
lung function, not significantly different from the atopics.
Only 9 patients did not have rhinitis. They had the lowest
lung function with a FEV1pre-BD1.22(1.10-1.38), with a loss
of 60mL/year in FEV1pre-BD.After 9 years of regular treat-
ment ACQ score improved significantly [median points
(IR) 0.83(0.33-1.83)].
Conclusions
Long term treatment controls symptoms of asthma and
protects against decline in lung function. Uncontrolled
asthma, nonatopic asthma and the absence of rhinitis
appear to be related to a trend to a increased decline,
though not statistically significant.
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